Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin

F. M. Pulcinelli, S. Riondino, A. Celestini, P. Pignatelli, E. Trifirò, L. Di Renzo, F. Violi

Research output: Contribution to journalArticle

Abstract

Background: Patients treated with aspirin may have a reduced sensitivity to its antiplatelet effect. The mechanism accounting for such a reduced sensitivity might involve an impaired interaction of aspirin with cyclooxygenase-1 (COX)-1. Objective: We sought to investigate whether platelets from patients under chronic treatment with aspirin still produce TxA2 and whether there is any relationship between the eventual persistent TxA2 formation and platelet aggregation. Finally, whether platelet-derived TxA2 can be inhibited by in vitro addition of aspirin. Methods: Collagen-induced platelet aggregation and thromboxane-A2 (TxA2) were measured in 196 patients treated with aspirin (100-330 mg day-1) because of previous vascular events or presence of risk factors of atherosclerosis. Results: Collagen-induced TxA2 production of the entire cohort was 128.7 ± 21.6 pg 10-8 cells, and was significantly correlated with platelet aggregation (Spearman's correlation coefficient = 0.44; P <0.0001). Patients in the highest quartile of TxA2 showed higher platelet response to collagen (P <0.0001) when compared with those in the lowest quartile. In a subgroup of 96 patients, platelets were treated in vitro with a TxA2 receptor antagonist ( 13-azaprostanoic acid) or aspirin before stimulation with collagen. 13-APA acid significantly inhibited platelet aggregation. Aspirin reduced (-72.9%) TxA2 production in patients with TxA2 values above the median but it was ineffective in those with TxA2 values below the median. Conclusion: In some patients chronically treated with aspirin platelet production of TxA2 may persist and account for enhanced platelet aggregation. Incomplete inhibition of COX-1 seems to be implicated in persistent TxA2 production.

Original languageEnglish
Pages (from-to)2784-2789
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Volume3
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Thromboxane A2
Aspirin
Blood Platelets
Platelet Aggregation
Collagen
Cyclooxygenase 1
Prostaglandin H2 Receptors Thromboxane A2
Blood Vessels
Atherosclerosis

Keywords

  • Aspirin
  • Platelet aggregation
  • Platelets
  • Thromboxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. / Pulcinelli, F. M.; Riondino, S.; Celestini, A.; Pignatelli, P.; Trifirò, E.; Di Renzo, L.; Violi, F.

In: Journal of Thrombosis and Haemostasis, Vol. 3, No. 12, 12.2005, p. 2784-2789.

Research output: Contribution to journalArticle

Pulcinelli, F. M. ; Riondino, S. ; Celestini, A. ; Pignatelli, P. ; Trifirò, E. ; Di Renzo, L. ; Violi, F. / Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. In: Journal of Thrombosis and Haemostasis. 2005 ; Vol. 3, No. 12. pp. 2784-2789.
@article{c8b3014eb7a34e5bbae4e8a266adf2ee,
title = "Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin",
abstract = "Background: Patients treated with aspirin may have a reduced sensitivity to its antiplatelet effect. The mechanism accounting for such a reduced sensitivity might involve an impaired interaction of aspirin with cyclooxygenase-1 (COX)-1. Objective: We sought to investigate whether platelets from patients under chronic treatment with aspirin still produce TxA2 and whether there is any relationship between the eventual persistent TxA2 formation and platelet aggregation. Finally, whether platelet-derived TxA2 can be inhibited by in vitro addition of aspirin. Methods: Collagen-induced platelet aggregation and thromboxane-A2 (TxA2) were measured in 196 patients treated with aspirin (100-330 mg day-1) because of previous vascular events or presence of risk factors of atherosclerosis. Results: Collagen-induced TxA2 production of the entire cohort was 128.7 ± 21.6 pg 10-8 cells, and was significantly correlated with platelet aggregation (Spearman's correlation coefficient = 0.44; P <0.0001). Patients in the highest quartile of TxA2 showed higher platelet response to collagen (P <0.0001) when compared with those in the lowest quartile. In a subgroup of 96 patients, platelets were treated in vitro with a TxA2 receptor antagonist ( 13-azaprostanoic acid) or aspirin before stimulation with collagen. 13-APA acid significantly inhibited platelet aggregation. Aspirin reduced (-72.9{\%}) TxA2 production in patients with TxA2 values above the median but it was ineffective in those with TxA2 values below the median. Conclusion: In some patients chronically treated with aspirin platelet production of TxA2 may persist and account for enhanced platelet aggregation. Incomplete inhibition of COX-1 seems to be implicated in persistent TxA2 production.",
keywords = "Aspirin, Platelet aggregation, Platelets, Thromboxane",
author = "Pulcinelli, {F. M.} and S. Riondino and A. Celestini and P. Pignatelli and E. Trifir{\`o} and {Di Renzo}, L. and F. Violi",
year = "2005",
month = "12",
doi = "10.1111/j.1538-7836.2005.01633.x",
language = "English",
volume = "3",
pages = "2784--2789",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin

AU - Pulcinelli, F. M.

AU - Riondino, S.

AU - Celestini, A.

AU - Pignatelli, P.

AU - Trifirò, E.

AU - Di Renzo, L.

AU - Violi, F.

PY - 2005/12

Y1 - 2005/12

N2 - Background: Patients treated with aspirin may have a reduced sensitivity to its antiplatelet effect. The mechanism accounting for such a reduced sensitivity might involve an impaired interaction of aspirin with cyclooxygenase-1 (COX)-1. Objective: We sought to investigate whether platelets from patients under chronic treatment with aspirin still produce TxA2 and whether there is any relationship between the eventual persistent TxA2 formation and platelet aggregation. Finally, whether platelet-derived TxA2 can be inhibited by in vitro addition of aspirin. Methods: Collagen-induced platelet aggregation and thromboxane-A2 (TxA2) were measured in 196 patients treated with aspirin (100-330 mg day-1) because of previous vascular events or presence of risk factors of atherosclerosis. Results: Collagen-induced TxA2 production of the entire cohort was 128.7 ± 21.6 pg 10-8 cells, and was significantly correlated with platelet aggregation (Spearman's correlation coefficient = 0.44; P <0.0001). Patients in the highest quartile of TxA2 showed higher platelet response to collagen (P <0.0001) when compared with those in the lowest quartile. In a subgroup of 96 patients, platelets were treated in vitro with a TxA2 receptor antagonist ( 13-azaprostanoic acid) or aspirin before stimulation with collagen. 13-APA acid significantly inhibited platelet aggregation. Aspirin reduced (-72.9%) TxA2 production in patients with TxA2 values above the median but it was ineffective in those with TxA2 values below the median. Conclusion: In some patients chronically treated with aspirin platelet production of TxA2 may persist and account for enhanced platelet aggregation. Incomplete inhibition of COX-1 seems to be implicated in persistent TxA2 production.

AB - Background: Patients treated with aspirin may have a reduced sensitivity to its antiplatelet effect. The mechanism accounting for such a reduced sensitivity might involve an impaired interaction of aspirin with cyclooxygenase-1 (COX)-1. Objective: We sought to investigate whether platelets from patients under chronic treatment with aspirin still produce TxA2 and whether there is any relationship between the eventual persistent TxA2 formation and platelet aggregation. Finally, whether platelet-derived TxA2 can be inhibited by in vitro addition of aspirin. Methods: Collagen-induced platelet aggregation and thromboxane-A2 (TxA2) were measured in 196 patients treated with aspirin (100-330 mg day-1) because of previous vascular events or presence of risk factors of atherosclerosis. Results: Collagen-induced TxA2 production of the entire cohort was 128.7 ± 21.6 pg 10-8 cells, and was significantly correlated with platelet aggregation (Spearman's correlation coefficient = 0.44; P <0.0001). Patients in the highest quartile of TxA2 showed higher platelet response to collagen (P <0.0001) when compared with those in the lowest quartile. In a subgroup of 96 patients, platelets were treated in vitro with a TxA2 receptor antagonist ( 13-azaprostanoic acid) or aspirin before stimulation with collagen. 13-APA acid significantly inhibited platelet aggregation. Aspirin reduced (-72.9%) TxA2 production in patients with TxA2 values above the median but it was ineffective in those with TxA2 values below the median. Conclusion: In some patients chronically treated with aspirin platelet production of TxA2 may persist and account for enhanced platelet aggregation. Incomplete inhibition of COX-1 seems to be implicated in persistent TxA2 production.

KW - Aspirin

KW - Platelet aggregation

KW - Platelets

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=29244442937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244442937&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2005.01633.x

DO - 10.1111/j.1538-7836.2005.01633.x

M3 - Article

C2 - 16359516

AN - SCOPUS:29244442937

VL - 3

SP - 2784

EP - 2789

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 12

ER -